Its original clinical trial showed 94 per cent efficacy. However, the vaccine manufacturer company said that they expect the most talked about booster shots to be necessary.
The vaccine manufacturer Moderna Inc said that its COVID-19 shot is approximately 93 per effective through six months after the second dose. Its original clinical trial showed 94 per cent efficacy. However, the vaccine manufacturer company said that they expect the most talked about booster shots to be necessary.
Meanwhile, Moderna's rival --- Pfizer Inc and BioNTech SE--- are pitching for the third shot to maintain protection against the novel coronavirus.
Speaking to the media, Moderna CEO Stephane Bancel had informed that they would not produce more than 1 billion doses of the vaccines per year. He further said that the capacity has been constrained for 2021 and will not be taking any more orders for this year. He added that the coronavirus vaccine is showing durable efficacy of 93% but recognize that Delta is a new threat, and we must remain vigilant.
On Wednesday, in pre-market trading, Moderna's shares fell 3.6 per cent to around $403.87.
As the Delta variant is grappling the world, the statement from CEO Bancel came amid the debate whether these additional doses would be safe and effective.
Speaking about the monetary values, in 2021, the company signed vaccine contracts worth $20 billion in sales and already has agreements for $12 billion in 2022.
In other news, the other vaccine manufacturer Pfizer is planning to seek authorization for a third shot soon.